Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago.
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges.
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
The FDA bestows a Breakthrough Therapy designation to Stoke Therapeutics' zorevunersen for the treatment of Dravet syndrome. Stock rises.
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 66.8% in Stoke Therapeutics (STOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.55 per share a year ago.
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026.
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.69 per share a year ago.
